Precision Biosciences (DTIL) Change in Account Payables (2018 - 2026)
Precision Biosciences (DTIL) posted quarterly Change in Account Payables of $648000.0 for Q1 2026, up 711.32% year-over-year from $79869.8 in Q1 2025, and up 161.71% quarter-over-quarter from -$1.0 million in Q4 2025.
Precision Biosciences (DTIL) Change in Account Payables (2018 - 2026) Analysis & Trends
Precision Biosciences (DTIL) has reported Change in Account Payables for 9 consecutive years, with $648000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Account Payables rose 711.32% year-over-year to $648000.0; the TTM figure through Mar 2026 stood at $17000.0 (up 117.0% YoY), while the FY2025 annual figure was -$737000.0, up 64.84% from the prior year.
- Change in Account Payables rose to $648000.0 in Q1 2026 per DTIL's latest filing, from -$1.0 million in the prior quarter.
- Across five years, Change in Account Payables topped out at $2.0 million in Q4 2023 and bottomed at -$2.1 million in Q1 2024.
- Historically, Change in Account Payables has averaged -$30823.5 across 5 years, with a median of $72000.0 in 2024.
- Annual changes were most pronounced in 2025 — Change in Account Payables slumped 1558.33% — and 2026, when it surged 711.32%.
- Precision Biosciences' Change in Account Payables stood at $340000.0 in 2022, then soared by 489.12% to $2.0 million in 2023, then sank by 96.41% to $72000.0 in 2024, then tumbled by 1558.33% to -$1.0 million in 2025, then jumped by 161.71% to $648000.0 in 2026.
- Business Quant data shows DTIL's Change in Account Payables at $648000.0 in Q1 2026, -$1.0 million in Q4 2025, and $220000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Precision Biosciences | 228.31 Mn | 140.77 Mn | - | -122,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -122,000.00 |
| Jun 30, 2026 | -122,000.00 |
| Mar 31, 2026 | 648,000.00 |
| Mar 31, 2026 | 648,000.00 |
| Dec 31, 2025 | -1.05 Mn |
| Dec 31, 2025 | -1.05 Mn |
| Sep 30, 2025 | 220,000.00 |
| Sep 30, 2025 | 220,000.00 |
| Jun 30, 2025 | 199,000.00 |
| Jun 30, 2025 | 199,000.00 |
| Mar 31, 2025 | -106,000.00 |
| Mar 31, 2025 | -106,000.00 |
| Dec 31, 2024 | 72,000.00 |
| Dec 31, 2024 | 72,000.00 |
| Sep 30, 2024 | -186,000.00 |
| Sep 30, 2024 | -186,000.00 |
| Jun 30, 2024 | 120,000.00 |
| Jun 30, 2024 | 120,000.00 |
| Mar 31, 2024 | -2.10 Mn |
| Mar 31, 2024 | -2.10 Mn |